# Characteristics of Patients Treated With Secukinumab for Moderate to Severe Plaque Psoriasis

> **NCT05650060** · — · COMPLETED · sponsor: **Novartis Pharmaceuticals** · enrollment: 163 (actual)

## Conditions studied

- Plaque Psoriasis

## Interventions

- **DRUG:** Secukinumab

## Key facts

- **NCT ID:** NCT05650060
- **Lead sponsor:** Novartis Pharmaceuticals
- **Sponsor class:** INDUSTRY
- **Phase:** —
- **Study type:** OBSERVATIONAL
- **Status:** COMPLETED
- **Start date:** 2021-01-20
- **Primary completion:** 2021-12-23
- **Final completion:** 2021-12-23
- **Target enrollment:** 163 (ACTUAL)
- **Last updated:** 2023-04-06


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT05650060

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT05650060, "Characteristics of Patients Treated With Secukinumab for Moderate to Severe Plaque Psoriasis". Retrieved via AI Analytics 2026-06-08 from https://api.ai-analytics.org/clinical/NCT05650060. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*